{
  "schema_version": 1,
  "kind": "drug_profile",
  "generic": "ramipril",
  "review_status": "reviewed",
  "origin": "openfda",
  "sections": {
    "adult": [
      {
        "text": "DOSAGE AND ADMINISTRATIO Hypertension: Initial dose is 2.5 mg to 20 mg once daily.",
        "source": "US FDA label for ramipril (Ramipril), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/ramipril.json",
        "verbatim": true
      },
      {
        "text": "The usual maintenance dose following titration is 2.5 mg to 20 mg daily as a single dose or equally divided doses ( 2.1 ).",
        "source": "US FDA label for ramipril (Ramipril), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/ramipril.json",
        "verbatim": true
      },
      {
        "text": "Reduction in the risk of myocardial infarction, stroke, or death from cardiovascular causes: 2.5 mg once daily for 1 week, 5 mg once daily for 3 weeks, and increased as tolerated to a maintenance dose of 10 mg once daily (2.2).",
        "source": "US FDA label for ramipril (Ramipril), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/ramipril.json",
        "verbatim": true
      }
    ],
    "child": [
      {
        "text": "Neonates with a history of in utero exposure to ramipril If oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function.",
        "source": "US FDA label for ramipril (Ramipril), section 'pediatric use', retrieved 2026-08-29",
        "cached_file": "labels/ramipril.json",
        "verbatim": true
      }
    ],
    "renal": [
      {
        "text": "Usual regimens of therapy with ramipril capsules may be followed in patients with estimated creatinine clearance >40 mL/min.",
        "source": "US FDA label for ramipril (Ramipril), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/ramipril.json",
        "verbatim": true
      },
      {
        "text": "Hypertension For patients with hypertension and renal impairment, the recommended initial dose is 1.25 mg ramipril capsules once daily.",
        "source": "US FDA label for ramipril (Ramipril), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/ramipril.json",
        "verbatim": true
      },
      {
        "text": "Heart Failure Post-Myocardial Infarction For patients with heart failure and renal impairment, the recommended initial dose is 1.25 mg ramipril capsules once daily.",
        "source": "US FDA label for ramipril (Ramipril), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/ramipril.json",
        "verbatim": true
      }
    ],
    "hepatic": [
      {
        "text": "No liver-impairment dose in this label. Not a statement that none is needed.",
        "source": "Read and found silent: the US FDA label for ramipril (Ramipril), retrieved 2026-08-29",
        "cached_file": "labels/ramipril.json",
        "verbatim": false
      }
    ],
    "pregnancy": [
      {
        "text": "Pregnancy Category D Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.",
        "source": "US FDA label for ramipril (Ramipril), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/ramipril.json",
        "verbatim": true
      },
      {
        "text": "Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations.",
        "source": "US FDA label for ramipril (Ramipril), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/ramipril.json",
        "verbatim": true
      },
      {
        "text": "Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.",
        "source": "US FDA label for ramipril (Ramipril), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/ramipril.json",
        "verbatim": true
      }
    ],
    "lactation": [
      {
        "text": "Ingestion of a single 10 mg oral dose of ramipril resulted in undetectable amounts of ramipril and its metabolites in breast milk.",
        "source": "US FDA label for ramipril (Ramipril), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/ramipril.json",
        "verbatim": true
      },
      {
        "text": "However, because multiple doses may produce low milk concentrations that are not predictable from a single dose, do not use ramipril in nursing mothers.",
        "source": "US FDA label for ramipril (Ramipril), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/ramipril.json",
        "verbatim": true
      },
      {
        "text": "Nursing mothers: Ramipril use is not recommended in nursing mothers ( 8.3 ). 8.1 Pregnancy Pregnancy Category D Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.",
        "source": "US FDA label for ramipril (Ramipril), section 'use in specific populations', retrieved 2026-08-29",
        "cached_file": "labels/ramipril.json",
        "verbatim": true
      }
    ]
  }
}